UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033538
Receipt number R000038242
Scientific Title A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.
Date of disclosure of the study information 2019/10/02
Last modified on 2018/12/21 16:30:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.

Acronym

A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.

Scientific Title

A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.

Scientific Title:Acronym

A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.

Region

Japan


Condition

Condition

No

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of excessive consumption of saw palmetto extract

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Doctor's questions, Physical measurement, Physical examination, Blood test, Urinalysis, Adverse event

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Saw palmetto extract, 4 weeks excessive consumption

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Healthy males and females aged 20 to 64 years-old.
(2) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1) Subjects who were diagnosed with serious disease (e.g., liver disease, kidney disease, digestive disease, heart disease, and/or peripheral vascular disease).
(2) Subjects with abnormal parameters in liver and/or kidney function.
(3) Subjects who had a gastrointestinal surgery.
(4) Subjects with a disease currently under treatment.
(5) Subjects with anemic.
(6) Subjects who play high intensity sports and/or are on a diet.
(7) Subjects who can't stop using functional foods (including Food for Specified Health Uses or Foods with Function Claims) and/or Specified quasi-drugs during the current study periods.
(8) Subjects who are under treatment with medications (including OTC or prescribed medication).
(9) Subjects who drink excessive alcohol, or who can't stop drinking from one day before each measurement.
(10) Subjects who are planning to become pregnant after imformed consent for the current study, pregnant or lactating.
(11) Subjects who are participating in other studies or planning to participate during the current study period.
(12) Subjects who are judged as unsuitable for the current study by the investigator for other reasons.

Target sample size

22


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Naoki Miura

Organization

Miura Clinic, Medical Corporation Kanonkai

Division name

Internal Medicine

Zip code


Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka, Japan

TEL

06-6135-5200

Email

mterashima@miula.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makoto Terashima

Organization

Oneness support Co., Ltd.

Division name

Clinical trial Division

Zip code


Address

Higashitenma building 4F, 1-7-17, Higashitenma, Kita-ku, Osaka, Japan

TEL

06-4801-8917

Homepage URL


Email

mterashima@oneness-sup.co.jp


Sponsor or person

Institute

Oneness support Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

BGG Japan Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 07 Month 23 Day

Date of IRB


Anticipated trial start date

2018 Year 07 Month 30 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 07 Month 27 Day

Last modified on

2018 Year 12 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038242


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name